A Phase 2 interventional study of DS-5141b in Duchenne Muscular Dystrophy, sponsored by Daiichi Sankyo Co., Ltd.. Active, not recruiting at 2 sites in Japan. Open to male participants aged 5 Years and older. Per ClinicalTrials.gov, last updated 2026-10-06.
Sponsored by Daiichi Sankyo Co., Ltd. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies in Muscular Dystrophy, Duchenne with a site in Japan — 2 open to participants now, 9 under way, 4 of them phase 3. Muscular Dystrophy, Duchenne · Japan.
Among the 27 studies in Muscular Dystrophy, Duchenne with a site in Japan, this one is the 23rd largest by planned enrollment of the 26 interventional ones that give a count, is one of 3 that started in 2020, is one of 8 in phase 2, and was the 18th registered.
482 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 107 are open to participants now.
Browse Muscular Dystrophy, Duchenne studies →2 of the 27 studies in Muscular Dystrophy, Duchenne with a site in Japan are open now. Recruiting first, the newest first:
NS Pharma, Inc. · Sites in Japan, United States, Australia and 4 more countries
Men only
Sarepta Therapeutics, Inc. · Sites in Japan, United States, Belgium and 6 more countries
Men only
A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →
Of the 65 Muscular Dystrophy, Duchenne studies recruiting now, 30 (46%) set no upper age limit and 33 (51%) stop at 75 or younger; 58 take children under 18; 11 take healthy volunteers.
This study: 5 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 13 · Phase 3 12 · Phase 4 1
First in 2007; this study’s year is marked. 3 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 8 is below the median of 25 across 333 interventional studies indexed under Muscular Dystrophy, Duchenne.
Median enrollment 62 across the 26 interventional studies. Of the 15 that completed or were terminated, 10 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 27 have an industry lead sponsor. The 10 most frequent:
This study is registered under Daiichi Sankyo Co., Ltd., one of the names counted as Daiichi Sankyo. Under that name alone:
Daiichi Sankyo Co., Ltd. is the lead sponsor of 73 studies on the registry; none are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 8 (80%) have results posted.
Daiichi Sankyo has 2 studies filed under Muscular Dystrophy, Duchenne — fewer than ten, so there is no comparison to draw.
4 of the studies in Muscular Dystrophy, Duchenne with a site in Japan that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05881408Phase 3Sarepta Therapeutics, Inc.A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD) | 2027-05-31 |
| NCT04433234Daiichi Sankyo Co., Ltd.Long-term, Extension Study of DS-5141b in Patients With Duchenne Muscular Dystrophy | 2027-01-31 |
| NCT05996003NS Pharma, Inc.NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy (DMD) | 2027-02-26 |
| NCT05135663Nippon Shinyaku Co., Ltd.Extension Study of NS-089/NCNP-02 in DMD | 2027-04-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 27 studies in Muscular Dystrophy, Duchenne with a site in Japan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multicenter, open-label, long-term, extension, phase 2 study to evaluate the safety and efficacy of long-term treatment with DS-5141b in patients with DMD who have completed DS5141-A-J101.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants who will receive DS-5141b 2.0 mg/kg once weekly.
Drug: DS-5141b
Participants who will receive DS-5141b 6.0 mg/kg once weekly.
Drug: DS-5141b
Administered via subcutaneous injection once weekly
Also known as: Renadirsen
Incidence of Adverse Events (AEs)
Time frame: From first injection to after the last injection of DS-5141b in this study (within approximately 2 years)
Change in distance walked during 6-minute walk test (6MWT)
Time frame: Every 3 months (within approximately 2 years)
Change in time to stand (TTSTAND)
Time frame: Every 3 months (within approximately 2 years)
Change in time in Timed up and go test
Time frame: Every 3 months (within approximately 2 years)
Change in time in 10-meter Run/Walk test
Time frame: Every 3 months (within approximately 2 years)
Change in score in the North Star Ambulatory Assessment (NSAA)
Time frame: Every 3 months (within approximately 2 years)
Change in score in the Performance of Upper Limb (PUL)
Time frame: Every 3 months (within approximately 2 years)
Change in Left Ventricular Ejection Fraction percentage (LVEF %)
Time frame: Every 6 months (within approximately 2 years)
Change in in Forced Vital Capacity (FVC) (percent predicted)
Time frame: Every 6 months (within approximately 2 years)
Change in Muscle Strength Measured by Quantitative Muscle Strength Assessment
Time frame: Every 3 months (within approximately 2 years)
Concentration of DS-5141a in plasma
Time frame: Every 3 months (within approximately 2 years)
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2020 (actual). Primary completion is estimated for Jan 2027, 79 months after the start.
Of 40 industry-sponsored phase 2 interventional studies under Muscular Dystrophy, Duchenne, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 42. This study's planned 79 months is above that.
Counting every sponsor, half of 47 studies reached it within 31 months; a quarter within 20 and three quarters within 42.
Completion moved once since we started tracking on Sep 25, 2026: Jan 2027 → Jan 2031, on Oct 6, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Muscular Dystrophy, Duchenne →